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South Africa (SA) is one of the 22 high tuberculosis (TB) burden 
countries that account for 83% of cases of TB worldwide.[1] Effective 
and rapid diagnosis of TB is an important strategy for reducing 
the burden of TB globally through early treatment initiation. Early 
initiation of treatment can reduce the opportunity for an infectious 
person to transmit TB within the community and improve patient 
treatment outcomes.[2,3] Xpert MTB/RIF is a diagnostic test for TB 
performed with the GeneXpert device (Cepheid, USA) – an automated, 
cartridge-based, nucleic amplification assay that detects both the 
Mycobacterium tuberculosis (MTB) organism and rifampicin resistance 
directly from sputum.[4] In ideal conditions, sample processing takes 
2 hours, with <20 minutes’ hands-on processing time.[5] Sputum testing 
by the Xpert MTB/RIF test may enable quicker diagnosis and earlier 
treatment initiation than sputum smear microscopy.[6]
Before availability of the Xpert MTB/RIF test, the diagnosis of 
pulmonary TB in resource-limited settings was based primarily on 
detection of acid-fast bacilli by sputum smear microscopy. Additional 
MTB culture might be performed to diagnose suspected smear-
negative TB and to detect suspected drug resistance.[7] Sputum smear 
microscopy is well suited for low-income countries because it is 
inexpensive and rapid, requires basic laboratory infrastructure and 
expertise, and is highly specific. However, sputum smear microscopy 
has relatively low diagnostic sensitivity and cannot detect drug 
resistance.[7] Sputum MTB culture in liquid or solid medium is more 
sensitive than smear microscopy and can detect drug resistance, but 
MTB culture is too slow to have an immediate impact on clinical 
management, requiring up to 8 weeks for laboratory processing. 
Additionally, MTB culture requires expensive equipment, advanced 
laboratory facilities and highly trained personnel.[4]
Since December 2010, the World Health Organization has 
recommended global rollout of the Xpert MTB/RIF test for diagnosis 
of pulmonary TB. In SA, Xpert MTB/RIF testing was officially 
launched in October 2011 and complete implementation was 
reported by 2013.[8] Per SA national guidelines, TB diagnosis before 
Xpert MTB/RIF rollout relied on sputum smear microscopy on two 
different samples from an individual suspected of having pulmonary 
TB, taken on different days or on the same day at least 1 hour apart. 
TB diagnosis after Xpert MTB/RIF rollout relies on a single ‘spot’ 
sputum sample. MTB culture was not routinely performed before 
Xpert MTB/RIF rollout (and is not routinely performed now), but 
was requested for investigation of HIV-infected individuals who 
might have paucibacillary TB disease, or if drug resistance was 
suspected. All sputum samples were collected by staff at local primary 
healthcare facilities and processed by a regional National Health 
Laboratory Service (NHLS) laboratory that generated a paper-based 
result for the clinic.[9]
Under research conditions, the Xpert MTB/RIF test greatly 
accelerates the time to laboratory diagnosis compared with MTB 
culture,[3,10] so that time to TB treatment initiation could potentially 
be reduced significantly – particularly for patients with sputum 
smear-negative TB disease, who would rely on MTB culture for 
diagnosis. Additionally, Xpert MTB/RIF has approximately two-fold 
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Background. The Xpert MTB/RIF test shortens the time to microbiological confirmation of pulmonary tuberculosis (TB) under research 
conditions.
Objective. To evaluate the field impact of Xpert MTB/RIF rollout on TB diagnostic yield and time to treatment in a South African (SA) 
community.
Methods. We compared TB investigation outcomes for 6-month calendar periods before and after Xpert MTB/RIF rollout in a semi-rural 
area of SA. The proportion of adult patients who tested positive by sputum smear microscopy, liquid culture or Xpert MTB/RIF and 
the proportion of positive sputum smear, liquid culture or Xpert MTB/RIF tests were compared. Secondary outcomes included time to 
laboratory diagnosis and treatment initiation. Data were collected from the National Health Laboratory Service database and from the 
Western Cape Provincial Department of Health TB register.
Results. Regional rollout of Xpert MTB/RIF testing occurred in 2013. Of the 15 629 patients investigated in the post-rollout period, 7.9% 
tested positive on GeneXpert, compared with 6.4% of the 10 741 investigated in the pre-rollout period who tested positive by sputum smear 
microscopy (p<0.001). Median laboratory processing time was <1 day for Xpert MTB/RIF (interquartile range (IQR) 0 - 1) compared with 
1 day (IQR 0 - 16) for sputum smear microscopy (p=0.001). The median time to TB treatment initiation was 4 days (IQR 2 - 8) after rollout 
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Conclusions. Patients investigated for suspected pulmonary TB were more likely to be diagnosed after rollout of Xpert MTB/RIF testing, 
although the benefit to diagnostic yield was modest, and Xpert MTB/RIF testing was associated with a marginal improvement in time to 
treatment initiation.
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higher sensitivity than sputum smear microscopy.[10,11] For these 
reasons it was hoped that Xpert MTB/RIF would be a ‘game-changer’ 
for TB control.[7] However, the majority of data have been derived 
from ideal research conditions, and it is unclear what impact Xpert 
MTB/RIF has had in real-world field settings. Initial reports indicate 
that the SA Xpert MTB/RIF rollout has not contributed to significant 
improvement in mortality of patients investigated for pulmonary TB.[12]
Objective
To determine the impact of Xpert MTB/RIF rollout on yield of TB 
case detection, time to diagnosis and time to treatment initiation in 
an SA community with a very high incidence of TB.[13,14]
Methods
This before-and-after observational cohort study evaluated the 
impact of rollout of Xpert MTB/RIF testing on the detection and 
treatment of new adult pulmonary TB cases in the Cape Winelands 
East district of the Western Cape Province, SA. The study protocol 
was approved by the University of Cape Town Human Research 
Ethics Committee (ref. no. 387/2014). Waiver for individual consent 
was granted for secondary data analysis of de-identified health 
systems data. The Cape Winelands East is a semi-rural area with 
a very high estimated total TB case notification rate of 1 400 per 
100  000 population.[14] There are >60 primary healthcare facilities 
in the district. Data from all adults aged ≥18 years who presented at 
primary healthcare facilities and were suspected of having pulmonary 
TB were included for potential analysis. Analyses were conducted 
for the period May - November in the calendar years 2012 and 
2014. These corresponding 6-month periods were selected in order 
to bracket Xpert MTB/RIF implementation in the Cape Winelands 
East district, which occurred during 2013, and to adjust for possible 
seasonal confounders.
Data from the two periods were compared for the proportion of 
patients investigated for TB who tested positive by sputum smear 
microscopy, liquid culture or Xpert MTB/RIF, and the proportion 
of sputum smear microscopy, liquid culture or Xpert MRB/RIF tests 
that were positive. Median time to laboratory diagnosis of pulmonary 
TB and median time to TB treatment initiation were compared, by 
test method and by period.
Data were collected from the electronic NHLS database that 
records all microbiological tests for TB in the region, including the 
type of test (sputum smear microscopy, Xpert MTB/RIF or liquid 
culture) and the result of each test. Unique individuals tested for 
pulmonary TB were identified by unique laboratory identifiers. 
For the analysis of proportion of patients investigated who tested 
positive, the denominator was the total number of individuals in the 
study period who were tested, and the numerator was the number of 
patients with a positive test by a particular method (sputum smear 
microscopy, Xpert MTB/RIF, liquid culture). For analysis of the 
proportion of positive tests, the denominator was the total number of 
tests in the study period, and the numerator the number of positive 
tests by a particular method. Data for the proportion of tests reported 
as invalid were collected to evaluate differences between sputum 
smear microscopy and Xpert MTB/RIF laboratory processes. An 
invalid result was obtained when a sample was lost or when a test was 
not completed, for whatever reason.
Secondary outcomes evaluated were median time to laboratory 
diagnosis and median time to TB treatment initiation. Time to 
laboratory diagnosis was defined as the time in days from when 
a sputum sample was collected to the time when that test result 
was reported. Time to TB treatment initiation was defined as the 
time from when a sputum sample was collected to the time when 
TB treatment was recorded as being initiated. The dates of sputum 
collection and generation of the result report were determined 
from dates captured on the NHLS electronic database. The dates of 
treatment initiation for individual patients were retrieved from an 
electronic TB register maintained by the Western Cape Provincial 
Department of Health.
Statistical tests for comparison of two proportions and Wilcoxon 
signed rank tests were used, with a threshold for significance of 0.05. 
Data were analysed using Stata 12 (StataCorp, USA).
Results
A total of 15 629 individuals with suspected TB were screened 
between May and November 2012 (pre-Xpert MTB/RIF rollout 
period) and 10 741 between May and November 2014 (post-rollout 
period). The median age and gender distribution of the patients 
investigated did not differ between the pre- and post-rollout periods 
(Table 1).
Of the patients tested for TB in the pre-rollout period, 13 279 
(85.0%) had sputum smear microscopy and 1 860 (11.9%) had 
additional liquid culture performed. Post-rollout, as expected, far 
fewer patients had sputum smear microscopy (n=2 542, 23.7%; 
p<0.001) or liquid culture (n=832, 7.7%; p<0.001) performed. The 
proportion of patients with positive sputum smear microscopy results 
was similar in the two periods (6.4% v. 6.2%; p=0.40), although the 
proportion of patients with positive liquid cultures was higher in the 
pre-rollout period than after rollout (1.5% v. 0.9%; p<0.001). In the 
post-rollout period, 7.9% of patients tested positive on Xpert MTB/
RIF, significantly more than by sputum smear microscopy in the pre-
Xpert MTB/RIF period in 2012 (7.9% v. 6.4%; p<0.001).
A total of 21 392 samples for TB investigation were processed 
in the pre-rollout period, compared with 14 858 in the post-
rollout period. The proportion of sputum smear microscopy-positive 
samples was similar before and after rollout (5.7% v. 5.0%; p=0.002), 
the proportion of positive liquid cultures was higher in the pre-
rollout period (3.2% v. 1.8%; p<0.001), and the proportion of positive 
Xpert MTB/RIF results (5.7%) in the post-rollout period was similar 
to the proportion of positive sputum smear microscopy results in the 
pre-rollout period (5.7%; p=0.95).
The median time to laboratory diagnosis for sputum smear 
microscopy in the pre-rollout period was 1 day compared with <1 
day for Xpert MTB/RIF in the post-rollout period. The median 
time to laboratory diagnosis by MTB culture was also slightly longer 
before than after rollout (39 v. 38 days; p<0.001). The median time 
to treatment initiation was 5 days before Xpert MTB/RIF rollout, 
compared with 4 days after rollout (p<0.001) (Table 2).
Discussion
We demonstrated that in a community-based study of the impact of 
Xpert MTB/RIF rollout in a high-burden primary healthcare setting 
in SA, patients with pulmonary TB were more likely to be diagnosed 
in the post-rollout period, when both Xpert and liquid culture were 
available, than in the pre-rollout period, when only sputum smear 
microscopy and liquid culture were available. Although the additional 
benefit to diagnostic yield was modest, it was also associated with a 
small improvement in time to laboratory diagnosis and time to TB 
treatment initiation, saving 1 day to start of treatment after Xpert 
MTB/RIF rollout, compared with the period in which sputum smear 
microscopy was the primary diagnostic modality. Although minor, 
this improvement in time to treatment may be clinically important 
in view of the very high incidence of TB disease in this region 
(1 400/100 000 population per year).[14] Our findings are consistent 
with other studies[6,15,16] that have shown that application of Xpert 
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MTB/RIF in a primary healthcare programmatic setting can improve 
the rate of TB case detection and reduce time to TB diagnosis.
We also observed a reduction in the number of sputum samples 
sent for testing (30.5% less) and the number of persons tested for 
TB (31.3% less) after Xpert MTB/RIF rollout (Table 1), with a 
consequent reduction in workload for TB clinic staff and laboratory 
staff in the latter period. However, we could not determine whether 
this decline reflected a true decline in the community burden of TB 
disease, and a corresponding reduction in persons presenting to the 
primary healthcare clinics with suspected TB, or was due to a change 
in TB screening practices, since pre-rollout sampling required two 
sputum samples. As expected, fewer sputum samples were sent for 
smear microscopy in the post-rollout period, but the proportion of 
positive smear results in both analysis periods was similar, implying 
that the rate of TB disease among investigated patients did not 
change, and therefore that the higher proportion of detected TB 
cases in the post-rollout period was due to more sensitive diagnostic 
testing using Xpert MTB/RIF. However, although the proportion of 
individuals screened for TB who had MTB culture performed was 
higher before than after Xpert MTB/RIF rollout, the MTB culture 
positivity rate followed the same trend (1.5% v. 0.9%; p<0.001). This 
finding might be explained if patients in the later period were slightly 
more paucibacillary, but not sufficiently so to make an impact on the 
rate of sputum smear positivity. A consequence of Xpert MTB/RIF 
rollout was decreased demand for MTB culture testing, which we 
hypothesise may be due to increased diagnostic confidence in Xpert 
MTB/RIF and/or the fact that Xpert MTB/RIF tests for rifampicin 
susceptibility, with less reliance on MTB culture to exclude drug-
resistant organisms.
The rollout of Xpert MTB/RIF testing at primary healthcare 
level was reportedly completed in this community by 2013, with a 
corresponding change in the recommended TB testing algorithm 
from sputum smear microscopy to Xpert MTB/RIF. However, we 
observed that almost a quarter of individuals with suspected TB 
who underwent screening in the post-rollout period still underwent 
sputum smear microscopy and not Xpert MTB/RIF testing. This 
finding indicates incomplete uptake of the new guidelines,[16] possibly 
owing to a GeneXpert cartridge shortage in 2013.[15] A forecast 
Table 1. Patients investigated for suspected pulmonary TB* 
Variable
Individuals with suspected TB Sputum samples
May - November 2012 May - November 2014 p-value May - November 2012 May - November 2014
Denominator, N 15 629 10 741 0.11 21 392 14 858
Sex, n (%)
Male 8 065 (51.6) 5 833 (54.3) 11 030 (51.6) 7 949 (53.5)
Female 7 179 (45.9) 4 731 (44.1) 9 857 46.1) 6 693 (45.1)
Unknown 385 (2.5) 216 (2.0) 505 (2.4) 216 (1.5)
Age (yr), median (IQR) (range) 37 (28 - 47) (18 - 87) 36 (28 - 46) (18 - 87) 36 (28 - 47) (18 - 90) 36 (28 - 46) (18 - 87)
Xpert MTB RIF, n (%)
Xpert done n/a 6 336 (59.0) n/a 6 336 (42.6)
Xpert negative n/a 5 471 (50.9) n/a 5 471 (36.8)
Xpert invalid n/a 14 (0.1) n/a 14 (0.1)
Xpert positive n/a 851 (7.9 n/a 851 (5.7)
Sputum smear, n (%)
Smear done 13 279 (85.0) 2 542 (23.7) 15 620 (73.0) 3 609 (24.3)
Smear negative 11 498 (73.6) 1 286 (12.0) 13 369 (62.5) 1 716 (11.5)
Smear invalid 775 (5.0) 592 (5.5) 1 029 (4.8) 1 155 (7.8)
Smear positive 1 006 (6.4) 664 (6.2) 0.40 1 222 (5.7) 738 (5.0)
MTB culture, n (%)
Culture done 1 860 (11.9) 832 (7.7) <0.001 4 245 (19.8) 2 209 (14.9)
Culture negative 1 471 (9.2) 664 (6.2) 3 187 (14.9) 1 748 (11.8)
Culture invalid 152 (1.0) 72 (0.7) 367 (1.7) 189 (1.3)
Culture positive 237 (1.5) 96 (0.9) <0.001 691 (3.2) 272 (1.8)
TB = tuberculosis; IQR = interquartile range; n/a = not applicable.
*May - November 2012 represents the pre-rollout period before Xpert MTB/RIF implementation and May - November 2014 the post-rollout period after implementation.
Table 2. Median time to pulmonary TB diagnosis (TTD) and TB treatment initiation (TTI) in patients screened for suspected 
pulmonary TB*
May - November 2012 May - November 2014 p-value
Xpert MTB/RIF
TTD (d), median (IQR) n/a 0 (0 - 1)
Sputum smear
TTD (d), median (IQR) 1 (0 - 16) 2 (1 - 22) <0.001
Culture
TTD (d), median (IQR) 39 (37 - 40) 38 (37 - 40) <0.001
TTI (d), median (IQR) 5 (2 - 14) 4 (2 - 8) <0.001
TB = tuberculosis; IQR = interquartile range; n/a = not applicable.
*May - November 2012 represents the pre-rollout period before Xpert MTB/RIF implementation and May - November 2014 the post-rollout period after implementation.
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cart ridge price reduction in 2012 caused some countries to delay 
shipments, with a resultant break in supply and temporary reversion 
to first-line sputum smear microscopy testing.[15] Creswell et al.[15] 
also identified lack of or poor infrastructure and interrupted power 
supply as key barriers to Xpert MTB/RIF implementation. Additional 
local infrastructure improvements to address issues of uninterrupted 
electricity supply, climate control, work-space security, ventilation 
and dust control were required to set up GeneXpert machines. Unlike 
smear and culture testing, Xpert testing requires an uninterrupted 
power supply for the duration of the testing cycle.[15]
Study strengths and limitations
The main strengths of our study are that it was pragmatic, based 
on actual TB programmatic data in a field setting, and represents 
translation value at primary healthcare level in an endemic 
community. The benefits, or lack of benefit, of programmatic rollout 
of Xpert MTB/RIF at community level cannot be assumed from 
national-level statistics. However, one limitation of our study was 
that we could not identify the number of tests and the types of tests 
performed on each individual with suspected TB in this community; 
rather, we measured the total number of individuals investigated and 
number of samples processed. While efforts were made to merge 
databases that captured individual patient-level sputum smear 
microscopy, Xpert MTB/RIF, and MTB culture results, this was 
not always technically possible. For example, since all Xpert MTB/
RIF laboratory identifiers were unique, we could not link Xpert 
MTB/RIF laboratory identifiers to individual patient sputum smear 
microscopy or MTB culture results. Another limitation of our study 
was the non-availability of HIV incidence for our study periods, 
with the latest HIV transmission rate only known for 2016 in the 
Western Cape (1.4%). It is unclear whether the decline in TB testing 
with Xpert MTB/RIF may be related to improved control of the HIV 
epidemic.
Conclusion
In summary, we found that rollout of Xpert MTB/RIF in an 
SA community with a very high TB burden led to a modest 
improvement in the rate of detection of pulmonary TB and slightly 
more rapid treatment initiation among individuals screened at 
primary healthcare clinics. These benefits were associated with a 
reduced TB investigation workload for clinic and laboratory staff. 
These findings support continued use of this diagnostic test in 
the TB control programme and continued attempts to facilitate 
universal implementation in SA communities, where marginal 
systemic improvements may translate to major individual patient 
benefit.
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